Free Trial

D.A. Davidson & CO. Has $568,000 Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Recursion Pharmaceuticals logo with Medical background

D.A. Davidson & CO. boosted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 571.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 107,432 shares of the company's stock after buying an additional 91,438 shares during the period. D.A. Davidson & CO.'s holdings in Recursion Pharmaceuticals were worth $568,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Kinnevik AB publ boosted its holdings in Recursion Pharmaceuticals by 12.8% during the first quarter. Kinnevik AB publ now owns 13,434,171 shares of the company's stock worth $71,067,000 after buying an additional 1,528,503 shares during the last quarter. Clear Creek Financial Management LLC boosted its stake in Recursion Pharmaceuticals by 9.8% during the 1st quarter. Clear Creek Financial Management LLC now owns 21,315 shares of the company's stock worth $113,000 after acquiring an additional 1,907 shares during the last quarter. PDS Planning Inc acquired a new position in Recursion Pharmaceuticals during the first quarter valued at approximately $69,000. Sequoia Financial Advisors LLC acquired a new position in Recursion Pharmaceuticals during the first quarter valued at approximately $67,000. Finally, Cambridge Investment Research Advisors Inc. increased its stake in Recursion Pharmaceuticals by 33.1% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 117,120 shares of the company's stock valued at $620,000 after purchasing an additional 29,136 shares in the last quarter. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Stock Down 7.7%

RXRX traded down $0.44 during trading on Friday, reaching $5.28. The company had a trading volume of 31,496,533 shares, compared to its average volume of 16,582,415. Recursion Pharmaceuticals, Inc. has a 12 month low of $3.79 and a 12 month high of $12.36. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.11 and a quick ratio of 4.11. The business's fifty day moving average price is $4.82 and its 200 day moving average price is $6.08. The company has a market cap of $2.15 billion, a P/E ratio of -2.98 and a beta of 0.91.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The firm had revenue of $14.75 million for the quarter, compared to the consensus estimate of $18.12 million. During the same quarter last year, the company posted ($0.39) EPS. Recursion Pharmaceuticals's revenue for the quarter was up 7.2% on a year-over-year basis. Equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Morgan Stanley started coverage on shares of Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They set an "equal weight" rating and a $5.00 price target on the stock. Needham & Company LLC reiterated a "buy" rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Tuesday. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $7.00.

Get Our Latest Stock Report on Recursion Pharmaceuticals

About Recursion Pharmaceuticals

(Free Report)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

See Also

Institutional Ownership by Quarter for Recursion Pharmaceuticals (NASDAQ:RXRX)

Should You Invest $1,000 in Recursion Pharmaceuticals Right Now?

Before you consider Recursion Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.

While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Hot Growth Stocks to Watch Right Now!
Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines